Nitro-fatty acids suppress ischemic ventricular arrhythmias by preserving calcium homeostasis

Nitro-fatty acids are electrophilic anti-inflammatory mediators which are generated during myocardial ischemic injury. Whether these species exert anti-arrhythmic effects in the acute phase of myocardial ischemia has not been investigated so far. Herein, we demonstrate that pretreatment of mice with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2020-09, Vol.10 (1), p.15319, Article 15319
Hauptverfasser: Mollenhauer, Martin, Mehrkens, Dennis, Klinke, Anna, Lange, Max, Remane, Lisa, Friedrichs, Kai, Braumann, Simon, Geißen, Simon, Simsekyilmaz, Sakine, Nettersheim, Felix S., Lee, Samuel, Peinkofer, Gabriel, Geisler, Anne C., Geis, Bianca, Schwoerer, Alexander P., Carrier, Lucie, Freeman, Bruce A., Dewenter, Matthias, Luo, Xiaojing, El-Armouche, Ali, Wagner, Michael, Adam, Matti, Baldus, Stephan, Rudolph, Volker
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Nitro-fatty acids are electrophilic anti-inflammatory mediators which are generated during myocardial ischemic injury. Whether these species exert anti-arrhythmic effects in the acute phase of myocardial ischemia has not been investigated so far. Herein, we demonstrate that pretreatment of mice with 9- and 10-nitro-octadec-9-enoic acid (nitro-oleic acid, NO 2 -OA) significantly reduced the susceptibility to develop acute ventricular tachycardia (VT). Accordingly, epicardial mapping revealed a markedly enhanced homogeneity in ventricular conduction. NO 2 -OA treatment of isolated cardiomyocytes lowered the number of spontaneous contractions upon adrenergic isoproterenol stimulation and nearly abolished ryanodine receptor type 2 (RyR2)-dependent sarcoplasmic Ca 2+ leak. NO 2 -OA also significantly reduced RyR2-phosphorylation by inhibition of increased CaMKII activity. Thus, NO 2 -OA might be a novel pharmacological option for the prevention of VT development.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-020-71870-6